Enanta Pharmaceuticals (ENTA) Competitors $6.05 -0.04 (-0.66%) Closing price 04:00 PM EasternExtended Trading$6.05 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA vs. MNMD, SAGE, UPB, DNA, ABVX, RGNX, PGEN, CGEM, SIGA, and AMLXShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Mind Medicine (MindMed) (MNMD), Sage Therapeutics (SAGE), Upstream Bio (UPB), Ginkgo Bioworks (DNA), ABIVAX Société Anonyme (ABVX), REGENXBIO (RGNX), Precigen (PGEN), Cullinan Therapeutics (CGEM), SIGA Technologies (SIGA), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Mind Medicine (MindMed) Sage Therapeutics Upstream Bio Ginkgo Bioworks ABIVAX Société Anonyme REGENXBIO Precigen Cullinan Therapeutics SIGA Technologies Amylyx Pharmaceuticals Enanta Pharmaceuticals (NASDAQ:ENTA) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Does the media refer more to ENTA or MNMD? In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 2 mentions for Mind Medicine (MindMed). Mind Medicine (MindMed)'s average media sentiment score of 0.94 beat Enanta Pharmaceuticals' score of 0.93 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mind Medicine (MindMed) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ENTA or MNMD? Enanta Pharmaceuticals currently has a consensus price target of $17.25, suggesting a potential upside of 185.12%. Mind Medicine (MindMed) has a consensus price target of $25.11, suggesting a potential upside of 281.05%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher probable upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.23 Which has more risk & volatility, ENTA or MNMD? Enanta Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Is ENTA or MNMD more profitable? Mind Medicine (MindMed) has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -157.57%. Mind Medicine (MindMed)'s return on equity of -47.56% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-157.57% -75.53% -27.30% Mind Medicine (MindMed) N/A -47.56%-35.55% Which has stronger valuation & earnings, ENTA or MNMD? Mind Medicine (MindMed) has lower revenue, but higher earnings than Enanta Pharmaceuticals. Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$66.59M1.94-$116.04M-$4.95-1.22Mind Medicine (MindMed)N/AN/A-$95.73M-$2.08-3.17 Do insiders & institutionals believe in ENTA or MNMD? 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor ENTA or MNMD? Enanta Pharmaceuticals received 265 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 93.22% of users gave Mind Medicine (MindMed) an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes32056.94% Underperform Votes24243.06% Mind Medicine (MindMed)Outperform Votes5593.22% Underperform Votes46.78% SummaryMind Medicine (MindMed) beats Enanta Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.07M$6.69B$5.47B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.227.3222.5118.54Price / Sales1.94241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book1.156.486.734.25Net Income-$116.04M$143.41M$3.22B$248.18M7 Day Performance6.70%2.30%1.58%1.25%1 Month Performance13.72%7.14%4.05%3.76%1 Year Performance-55.38%-2.61%15.75%5.28% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals3.9335 of 5 stars$6.05-0.7%$17.25+185.1%-55.7%$129.07M$66.59M-1.22160Upcoming EarningsNews CoveragePositive NewsMNMDMind Medicine (MindMed)2.3094 of 5 stars$6.36+2.1%$25.11+294.8%-32.9%$479.34MN/A-2.8140Upcoming EarningsPositive NewsSAGESage Therapeutics3.7284 of 5 stars$7.77-0.3%$8.81+13.4%-47.7%$477.71M$41.24M-1.18690Earnings ReportAnalyst RevisionNews CoverageUPBUpstream BioN/A$8.78+4.6%$56.50+543.5%N/A$471.39M$2.37M0.0038News CoveragePositive NewsDNAGinkgo Bioworks0.6002 of 5 stars$8.02+2.3%$4.58-43.0%-79.3%$465.43M$227.04M-0.61640Upcoming EarningsNews CoverageABVXABIVAX Société Anonyme2.3898 of 5 stars$7.26+6.1%$38.00+423.4%-52.5%$460.42MN/A0.0061Analyst ForecastNews CoveragePositive NewsRGNXREGENXBIO4.4729 of 5 stars$9.13-0.2%$31.63+246.4%-37.4%$457.57M$83.33M-1.82370Upcoming EarningsNews CoveragePositive NewsPGENPrecigen3.677 of 5 stars$1.55+3.3%$7.00+351.6%+18.2%$455.77M$3.93M-2.82190News CoveragePositive NewsCGEMCullinan Therapeutics2.6638 of 5 stars$7.76-4.7%$34.80+348.5%-69.3%$454.06MN/A-2.7330Analyst RevisionNews CoveragePositive NewsSIGASIGA Technologies1.8584 of 5 stars$6.35-2.3%N/A-37.1%$453.65M$138.72M5.2940Upcoming EarningsOptions VolumePositive NewsAMLXAmylyx Pharmaceuticals2.8637 of 5 stars$5.01-6.5%$8.00+59.7%+182.3%$443.90M$87.37M-1.31200Upcoming Earnings Related Companies and Tools Related Companies MNMD Competitors SAGE Competitors UPB Competitors DNA Competitors ABVX Competitors RGNX Competitors PGEN Competitors CGEM Competitors SIGA Competitors AMLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTA Stock Free ENTA Stock Alerts